Mankind Pharma Ltd
NSE:MANKIND
Operating Margin
Mankind Pharma Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
971.5B INR |
21%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
236.5B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
177B GBP |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
36%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199.7B CHF |
32%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
25%
|
Mankind Pharma Ltd
Glance View
Mankind Pharma Ltd. has carved a unique niche in the pharmaceutical landscape of India, emerging as a formidable entity through an intriguing blend of affordability and accessibility. Founded in 1995 by R. C. Juneja, the company has steadily grown its portfolio to encompass a vast range of pharmaceutical products spanning prescription medications, over-the-counter (OTC) drugs, and consumer healthcare goods. Operating with a distinctive business model rooted in the ethos of delivering quality medicine at affordable prices, Mankind Pharma reaches deep into the densely populated tier II and tier III cities of India, ensuring that healthcare is accessible to the masses who need it the most. This strategic outreach, coupled with strong marketing and distribution networks, serves as a cornerstone of its business success. The company’s financial health is buoyed by its diversified product range, which caters to multiple therapeutic areas including antibiotics, cardiovascular, antifungal, and gastrointestinal, among others. Their robust R&D initiatives further reinforce their competitive edge, enabling them to continually introduce new and effective products that resonate with both healthcare providers and consumers. Revenue streams are not just confined to domestic borders; Mankind Pharma has been expanding its footprint internationally, penetrating markets across Asia, Africa, and the Americas. By striking a strategic balance between volume-driven pricing models and extensive market reach, Mankind Pharma not only emphasizes profitability but also solidifies its commitment to public health initiatives globally, thus creating a sustainable and progressive business trajectory.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Mankind Pharma Ltd's most recent financial statements, the company has Operating Margin of 21%.
You don't have any saved screeners yet